Highlights the basic biology of hepatitis C viral replication to identify novel targets for antiviral drug development.
Answers are grounded in this paper and cite their sources.
May guide preclinical HCV antiviral development; hypothesis-generating without clinical validation.
Chronic infection with the hepatitis C virus is a major health problem. Conventional therapy, with interferon-alpha is effective in only a minority of patients. The failure of current treatments has led to a major initiative to identify new antiviral agents. In the absence of a tissue culture model for hepatitis C infection the pharmaceutical industry has been obliged to investigate the basic biology of hepatitis C viral replication. Such studies have identified novel translational regulatory elements and new proteolytic enzymes which may serve as targets for new antiviral drugs.
No takes yet. Share an insight, caveat, or question.
B. E. Clarke (1995) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: